Physician profile
John J Miller
NPI 1841307527
$2,715,943.55
in general payments reported to CMS, 2019-2025
21 companies · $637K in 2025
The $637K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425K · 2020: $180K · 2021: $218K · 2022: $348K · 2023: $398K · 2024: $512K · 2025: $637K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Consulting Fee: $236K · Honoraria: $127K · Travel and Lodging: $117K · Food and Beverage: $37K · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,029,827.30 |
| Consulting Fee | $236,033.50 |
| Honoraria | $126,569.50 |
| Travel and Lodging | $116,656.16 |
| Food and Beverage | $37,185.54 |
| Education | $195.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $478,436.46 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $440,853.16 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $352,977.96 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $325,165.82 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $318,190.03 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $197,441.34 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $174,703.52 | 2019-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $141,919.37 | 2019-2021 | |
| Abbvie INC. | $132,322.48 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $131,379.48 | 2019-2021 | |
| Janssen Research & Development, LLC | $8,336.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,141.98 | 2023-2024 | |
| Biogen, INC. | $2,700.79 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,687.51 | 2019-2025 | Rexulti |
| Alkermes, INC. | $877.83 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $496.73 | 2019-2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $183.76 | 2019-2024 | Rexulti, Brintellix |
| Sage Therapeutics, LLC | $48.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.37 | 2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $23.39 | 2024 | |
| Janssen Scientific Affairs, LLC | $12.09 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.